TMEM126B

Across TCGA pan-cancer cohorts, TMEM126B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM126B data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TMEM126B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM126B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, COAD, and UCEC are the cancer types where TMEM126B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.052	0.710	<.001	48	view →
COAD	OS	Median	All	0.168	0.806	.002	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.306	.011	22	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM126B–BLCA (OS)

Open the BLCA breakdown →